Press Releases

PRESS RELEASE, September 24th 2024

TRiCares Announces First Topaz Implantation in EU Pivotal Study

TRiCares Announces First Topaz Implantation in EU Pivotal Study

PRESS RELEASE, July 25th 2024

TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones

TRiCares Raises $50m in Series D Financing to Support Upcoming Clinical Milestones

PRESS RELEASE, March 25th 2024

TRiCares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

TRiCares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer

PRESS RELEASE, December 21st 2023

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Patient with a Pacemaker

TRiCares Announces Successful Implantation of Minimally Invasive Topaz in Patient with Pacemaker Treatment for Tricuspid Regurgitation

PRESS RELEASE, December 6th 2022

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund

TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation

PRESS RELEASE, September 15th 2022

TRiCares Raises €47m in a First Closing of its Series C Financing

TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation.

PRESS RELEASE, August 30th 2022

TRiCares Announces First Successful Implantation

TRiCares Announces First Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in TRICURE Study

PRESS RELEASE, May 16th 2022

First Implantation in Canada

TRiCares Announces Successful Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Canada

PRESS RELEASE, April 25th 2022

First Implantation in Germany

TRiCares Announces Successful First in Human Implantation of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System in Germany

PRESS RELEASE, July 5th 2021

First Implantation Worldwide

TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System

PRESS RELEASE, June 4th 2018

Series B Financing Round

TRiCares Closes €22 Million ($25.4 Million) Series B Financing Round to Fund Development of Minimally Invasive Treatment of Tricuspid Regurgitation

PUBLICATION


First-in-human Implantation of the Topaz TTVR system   
EuroIntervention 2022;18, E. Teiger et al. DOI: 10.4244/EIJ-D-22-00277

download publication